Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
May 07 2021 - 4:18PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of May 2021
Commission File Number: 001-37452
CELYAD ONCOLOGY SA
(Translation of registrants name into English)
Rue Edouard
Belin 2
1435 Mont-Saint-Guibert, Belgium
(Address of principal executive offices)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Celyad Oncology SA
Financial and Operating Results
On May 6, 2021,
Celyad Oncology SA (the Company) issued a press release announcing its financial and operating results for the first quarter of 2021. A copy of the Companys press release is attached hereto as Exhibit 99.1 and is
incorporated herein by reference. The Companys interim consolidated statement of comprehensive income and interim consolidated statement of financial position for the first quarter of 2021 are attached hereto as Exhibit 99.2 and are
incorporated herein by reference.
Update on Horizon Discovery
As previously disclosed, Horizon Discovery Group plc / PerkinElmer, Inc. (Horizon/PKI) informed us they believe we are in material breach of our 2018 research
and development collaboration and license agreements. Horizon/PKI recently informed us that unless we are able to reach agreement regarding the purported material breach they may elect to serve us a notice of termination. We continue to believe that
any formal notice of termination would be without merit and we would expect to vigorously contest the validity and effectiveness of any such notice and the existence of any material breach. Any dispute under these agreements would be subject to
arbitration in The Hague under the International Chamber of Commerce Rules. We are currently in discussions with Horizon/PKI to settle the matter.
The
information contained in this Current Report on Form 6-K, including Exhibits 99.1 and 99.2, except for the quote of Filippo Petti contained in Exhibit 99.1, is hereby incorporated by reference into the
Companys Registration Statements on Forms F-3 (File No. 333-248464) and S-8 (File
No. 333-220737).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CELYAD ONCOLOGY SA
|
|
|
|
|
Date: May 7, 2021
|
|
|
|
By:
|
|
/s/ Filippo Petti
|
|
|
|
|
|
|
Filippo Petti
|
|
|
|
|
|
|
Chief Executive Officer and Financial Officer
|
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Mar 2024 to Apr 2024
Celyad Oncology (NASDAQ:CYAD)
Historical Stock Chart
From Apr 2023 to Apr 2024